Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Hard Copy Electronic Site License CNS Year in Review: 2001 Datamonitor, Jan 2002   Description     Table of Contents        Enquire before Buying    Send to a Friend   This Market Brief sets out the sales figures of the leading CNS drugs for 2001, together with the leading events, be they clinical trial results, product launches, patent expiries or court room battles which have helped to shape the market throughout the year. The major CNS disease markets are examined, namely Alzheimer’s disease, anticonvulsants, antidepressants, antipsychotics, migraine, multiple sclerosis, pain, and Parkinson’s disease. This brief paints a preliminary picture of the 2001 CNS market before the full yearly breakdowns have become available. Furthermore, it also provides a brief overview of the current trends in the CNS market and how individual markets may develop. The sales figures set out in this report are obtained from one of three sources. Priority was given to published 2001 results, however most of the figures presented are derived from primary research regarding quarterly sales, which were then projected to give a full year figure. However, in some cases it was not possible to obtain such figures. In these cases, the most up to date forecasts from Datamonitor’s reports were taken. Customers who bought this item also bought CNS Market: Year in Review - Sales Overview and Market News, 2000 Strategic Perspectives 2001: Neuropathic pain - Catch 22: high revenue potential but a high risk investment Drugs of Tomorrow 2001: Diabetes Strategic Perspectives 2001: Anticonvulsants - The Ever-Widening Treatment Spectrum Commercial Insight: Migraine - A Painful Future for the Triptans? The Rationale Behind Drug Reformulation: Five Case Studies and Overview of CNS Market and R&D Strategic Perspectives 2001: Vaccines Strategic Perspectives 2001: Dermatological Disorders - A Prototypic Model for Inflammatory and Autoimmune Diseases Market Dynamics 2001: Diabetes Strategic Perspective 2001: Female Cancers - Optimizing Market Opportunities Drugs of Tomorrow 2001: Migraine - Impact of the Novel Triptan Class on Acute Treatment Market Market Dynamics 2001: Cytotoxics

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster